Angiotensin-converting enzyme gene polymorphism in hypertensive rural population of Haryana, India

Background: Essential hypertension is a complex genetic disorder influenced by diverse environmental factors. Of the various physiological pathways affecting the homeostasis of blood pressure, the renin-angiotensin system (RAS) is known to play a critical role. Angiotensin-I converting enzyme (ACE) is a significant component of RAS and an insertion/deletion (I/D) polymorphism in its gene has been implicated in predisposition to hypertension. Objective: The present study is aimed to determine the association, if any, of ACE I/D polymorphism with essential hypertension in a rural population of Haryana, India. Materials and Methods: The blood samples were collected from the patients visiting M. M. Institute of Medical Sciences, Mullana, Haryana. DNA from the patients (106) and control (110) specimens were isolated, amplified by PCR and analyzed employing agarose gel electrophoresis. Results: There was no significant difference in the distribution of DD, II and I/D genotypes of ACE polymorphism in essential hypertensive patients (28.8, 25.5, and 46.2%) and their ethnically matched normal control (24.5, 30, and 45.5), respectively. The two groups also presented with very similar allelic frequencies and were also found to be in Hardy-Weinberg equilibrium. Conclusions: The present study demonstrates that ACE I/D polymorphism is not a risk factor for essential hypertension in the hitherto unstudied rural population of Haryana

Pancreatic laceration and portal vein thrombosis in blunt trauma abdomen

Injuries to the pancreas by blunt trauma are uncommon. The association of pancreatic injury with acute portal vein thrombosis secondary to blunt trauma abdomen is furthermore rare. The early diagnosis of the pancreas with injury to the portal vein is challenging and difficult. These injuries are associated with high morbidity and mortality, particularly if the diagnosis is delayed. Accurate and early diagnosis is therefore imperative and computed tomography plays a key role in detection. We present a case of child with a rare combination of pancreatic laceration and acute portal vein thrombosis following a blunt trauma to the abdomen. With extensive literature search we found no such cases has been described previously

Pancreatic laceration and portal vein thrombosis in blunt trauma abdomen

Injuries to the pancreas by blunt trauma are uncommon. The association of pancreatic injury with acute portal vein thrombosis secondary to blunt trauma abdomen is furthermore rare. The early diagnosis of the pancreas with injury to the portal vein is challenging and difficult. These injuries are associated with high morbidity and mortality, particularly if the diagnosis is delayed. Accurate and early diagnosis is therefore imperative and computed tomography plays a key role in detection. We present a case of child with a rare combination of pancreatic laceration and acute portal vein thrombosis following a blunt trauma to the abdomen. With extensive literature search we found no such cases has been described previously

University of Michigan Undergraduate Research Forum, Issue 2, Winter 2005

Articlehttp://deepblue.lib.umich.edu/bitstream/2027.42/96965/1/UMURF-Issue02_2005.pd

Perception and practices followed by AYUSH practitioners and health seekers for prevention of COVID-19: Cross-sectional analysis of an app-based data

Abstract AYUSH Sanjivani is a mobile application launched by the Ministry of AYUSH (MoA) to gather information regarding the utilization of AYUSH (Ayurveda, Yoga, Unani, Siddha, and Homeopathy) advocacies for the prevention of COVID-19 infection. A cross-sectional analysis of the data generated through this mobile application has been performed and presented in this article to examine the acceptability and extent of utilization of AYUSH preventive measures in India. Objectives: The objectives of this cross-sectional analysis was to determine the trends of the utilization of AYUSH measures by the beneficiaries as reported by AYUSH practitioners and by the practitioners themselves for the prevention of COVID-19 and to determine the benefit obtained in terms of self-reported parameters of general well being, the overall impact on general health and in preventing the onset of flu-like symptoms. Methods: A secondary data analysis was undertaken, utilizing the cross-sectional data generated through the AYUSH Sanjivani App from May to July 2020. The responses in terms of demographic profile, utilization pattern, benefits obtained, the interventions used and the data of beneficiaries in terms of geographic location and interventions prescribed were analyzed statistically to assess the trends of the utilization of AYUSH measures for prophylaxis. Results: Data of 74,568 AYUSH physicians and 1,35,21,245 beneficiaries/health seekers whose data were reported by 3623 AYUSH practitioners were used for analysis. AYUSH advocacies/measures were utilized by 69,195 (92.8%) physicians for prophylaxis. Samshamani Vati, Chyavanprash, and Arsenicum Album-30 were the most commonly used AYUSH interventions. Improvement in terms of appetite, bowel movements, sleep, mental well being, stamina, change in pre-existing disease, and change in disposition were reported by 42400 (61.3%) physicians. Maximum beneficiaries were from the state of Gujarat followed by Madhya Pradesh. Arsenicum Album-30 was the most commonly prescribed/distributed intervention among the beneficiaries/ health seekers. Conclusion: Maximum physicians have reported having benefited from the use of AYUSH prophylactic measures for the prevention of COVID-19. Moreover, a good proportion of the Indian population was provided the AYUSH prophylactic measures as recorded in the app

Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks.

Low-frequency coding DNA sequence variants in the proprotein convertase subtilisin/kexin type 9 gene (PCSK9) lower plasma low-density lipoprotein cholesterol (LDL-C), protect against risk of coronary heart disease (CHD), and have prompted the development of a new class of therapeutics. It is uncertain whether the PCSK9 example represents a paradigm or an isolated exception. We used the "Exome Array" to genotype >200,000 low-frequency and rare coding sequence variants across the genome in 56,538 individuals (42,208 European ancestry [EA] and 14,330 African ancestry [AA]) and tested these variants for association with LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides. Although we did not identify new genes associated with LDL-C, we did identify four low-frequency (frequencies between 0.1% and 2%) variants (ANGPTL8 rs145464906 [c.361C>T; p.Gln121(∗)], PAFAH1B2 rs186808413 [c.482C>T; p.Ser161Leu], COL18A1 rs114139997 [c.331G>A; p.Gly111Arg], and PCSK7 rs142953140 [c.1511G>A; p.Arg504His]) with large effects on HDL-C and/or triglycerides. None of these four variants was associated with risk for CHD, suggesting that examples of low-frequency coding variants with robust effects on both lipids and CHD will be limited

Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks

Low-frequency coding DNA sequence variants in the proprotein convertase subtilisin/kexin type 9 gene (PCSK9) lower plasma low-density lipoprotein cholesterol (LDL-C), protect against risk of coronary heart disease (CHD), and have prompted the development of a new class of therapeutics. It is uncertain whether the PCSK9 example represents a paradigm or an isolated exception. We used the "Exome Array" to genotype >200,000 low-frequency and rare coding sequence variants across the genome in 56,538 individuals (42,208 European ancestry [EA] and 14,330 African ancestry [AA]) and tested these variants for association with LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides. Although we did not identify new genes associated with LDL-C, we did identify four low-frequency (frequencies between 0.1% and 2%) variants (ANGPTL8 rs145464906 [c.361C>T; p.Gln121-], PAFAH1B2 rs186808413 [c.482C>T; p.Ser161Leu], COL18A1 rs114139997 [c.331G>A; p.Gly111Arg], and PCSK7 rs142953140 [c.1511G>A; p.Arg504His]) with large effects on HDL-C and/or triglycerides. None of these four variants was associated with risk for CHD, suggesting that examples of low-frequency coding variants with robust effects on both lipids and CHD will be limited